which has set the global standard for PCV2 protection for nearly 20 years, this new dual-antigen approach offers producers an additional option to protect their pigs and support long-term profitability.
PCV2 is one of the most prevalent and economically significant viruses in swine production. Porcine circovirus associated disease (PCVAD) is caused by the PCV2 virus and can lead to severe weight loss, difficulty breathing, and diarrhea. It impairs the immune system, enhancing co-infections and leaving pigs more susceptible to other swine diseases affecting the respiratory, reproductive and digestive systems.
While several genotypes have been identified, the industry has observed a clear shift over the past decade, with PCV2d becoming the predominant genotype in the U.S. and globally.1,2 The broad protection provided by INGELVAC CIRCOFLEX® AD was designed with this shifting landscape in mind, advancing pig health and sustaining viable businesses for producers.
Supporting pig producers through efficacy and convenience
“Our customers can count on us for continuous vaccine innovation. With INGELVAC CIRCOFLEX® AD, we’re further advancing protection against evolving PCV2 threats with both PCV2a and PCV2d antigens combined. These two genotypes are responsible for over 90% of clinical cases,1 and we are the first company to offer both antigens in a single dose,” said Gerard Ensink, Global Head of Swine at Boehringer Ingelheim. “We’ll continue to closely monitor PCV2 and other diseases impacting pig performance to help producers stay ahead of emerging risks.”
A vaccine that provides broad cross-protection is essential for effective PCV2 control. To maximize herd productivity, it is also important to manage co-infections, implement robust biosecurity measures, and maintain a thorough understanding of disease epidemiology.
“We’re excited to bring INGELVAC CIRCOFLEX® AD to the U.S. market first, delivering the latest innovation in PCV2 protection,” shared Steve Boren, Vice President, U.S. Livestock at Boehringer Ingelheim. “In an industry where disease is a constant challenge, this next-generation vaccine offers broader, safer, longer-lasting immunity against the most prevalent PCV2 genotypes and can help proactively strengthen a herd’s immune system to reduce the risk and impact of co-infections. INGELVAC CIRCOFLEX® AD reflects Boehringer Ingelheim’s long-standing commitment to PCV2 control and empowering producers to manage herd health with greater confidence.”
Boehringer Ingelheim - Animal Health business
Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society.
Boehringer Ingelheim - Animal Health business
Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society.
